Archived News Releases


2016 | 2015 | 2014 | 2013 | 2012 | 2011
Keyword Search
 
DateTitle 
12/20/12ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program
Award Will Advance ACADIA’s Selective ER-Beta Agonist as a Potential New Neuroprotective MS Therapy through Collaborative Research with UCLA SAN DIEGO--(BUSINESS WIRE)--Dec. 20, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will receive funding from Fast... 
Printer Friendly Version
12/12/12ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference Today, December 12, 2012
SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the Oppenheimer 23rd Annual Healthcare Conference later today, Wednesday, December 12, 2012, at 3:55 p.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. ... 
Printer Friendly Version
12/12/12ACADIA Pharmaceuticals Announces $86 Million Equity Financing
--Proceeds to Support Completion of Pimavanserin Phase III Program-- SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced a private placement equity financing pursuant to which ACADIA will receive gross proceeds of $86.4 million from... 
Printer Friendly Version
11/27/12ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy and Maintenance of Motor Control in Parkinson’s Patients Significant Improvements Also Observed in All Secondary and Exploratory Measures Conference Call and Webcast to Be Held Today, November 27, 2012, at 8:00 am Eastern Time SAN DIEGO--(BUSINESS WIRE)--Nov. 27, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced successful top-lin... 
Printer Friendly Version
11/26/12ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson’s Disease Psychosis Trial
SAN DIEGO--(BUSINESS WIRE)--Nov. 26, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, November 27, 2012 to present the top-line results from its pivotal Phase III trial with pimavanserin in patie... 
Printer Friendly Version
11/05/12ACADIA Pharmaceuticals Reports Third Quarter 2012 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2012. ACADIA reported a net loss of $2.4 million, or $0.04 per common share, for the third quarter of 2012... 
Printer Friendly Version
10/29/12ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012
ACADIA to Host Conference Call and Webcast on Monday, November 5, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended S... 
Printer Friendly Version
09/05/12ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis
Top-Line Data Expected in November 2012 SAN DIEGO--(BUSINESS WIRE)--Sep. 5, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis (PDP). ... 
Printer Friendly Version
08/29/12ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Aug. 29, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Stifel Nicolaus Healthcare Conference on Wednesday, September 5, 2012, at 3:50 p.m. Eastern Time at the Four S... 
Printer Friendly Version
08/08/12ACADIA Pharmaceuticals Reports Second Quarter 2012 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2012. ACADIA reported a net loss of $5.4 million, or $0.10 per common share, for the second quarter of 2012 co... 
Printer Friendly Version
08/01/12ACADIA Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 8, 2012
ACADIA to Host Conference Call and Webcast on Wednesday, August 8, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter... 
Printer Friendly Version
07/09/12ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer’s Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA’s proprietary product candidate currently in Phase III development for Parkinson’s disease psychosis, also may have ... 
Printer Friendly Version
07/09/12ACADIA Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012
SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 7th Annual JMP Securities Healthcare Conference on Friday, July 13, 2012, at 11:00 a.m. Eastern Time at The Peninsula Hotel in New York City. A live web... 
Printer Friendly Version
05/15/12ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012
SAN DIEGO--(BUSINESS WIRE)--May 15, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will host a live webcast of its Educational Program on Parkinson’s Disease Psychosis to be held with analysts and investors in New York City on Tuesday, May 22, 2012, from 12:00 p.m. to 1:15 p.m. Eastern Time. The program will be h... 
Printer Friendly Version
05/08/12ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 8, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012. ACADIA reported a net loss of $6.2 million, or $0.12 per common share, for the first quarter of 2012 compared to a net loss of $5.8 million, or $0.12 per common sha... 
Printer Friendly Version
05/01/12ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
ACADIA to Host Conference Call and Webcast on Tuesday, May 8, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--May 1, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2012 on Tuesday, May 8, 2012, after the U.S. financial... 
Printer Friendly Version
04/13/12ACADIA Pharmaceuticals to Present at the 19th Annual Future Leaders in the Biotech Industry Conference on April 20, 2012
SAN DIEGO, Apr 13, 2012 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 19th Annual Future Leaders in the Biotech Industry Conference on Friday, April 20, 2012, at 11:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York City.... 
Printer Friendly Version
03/28/12ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012
SAN DIEGO--(BUSINESS WIRE)--Mar. 28, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 11th Annual Needham Healthcare Conference on Tuesday, April 3, 2012, at 9:20 a.m. Eastern Time at The New York Palace Hotel in New York City. A live we... 
Printer Friendly Version
03/27/12ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease
SAN DIEGO--(BUSINESS WIRE)--Mar. 27, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has been awarded a new grant from The Michael J. Fox Foundation (MJFF) for the further development of Nurr1-RXR selective agonists for the treatment of Parkinson’s disease. The grant of ... 
Printer Friendly Version
03/06/12ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
SAN DIEGO--(BUSINESS WIRE)--Mar. 6, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2011. ACADIA reported a net loss of $5.3 million, or $0.10 per common share, for the fourth quarter of 2011... 
Printer Friendly Version
03/05/12ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is currently focused on the discovery of new therapeutics for glaucoma and... 
Printer Friendly Version
02/29/12ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Feb. 29, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: The Cowen and Company 32nd Annual Health Care Conference on Wednesday, March 7, 2012, at 10:00 a.... 
Printer Friendly Version
02/28/12ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012
ACADIA to Host Conference Call and Webcast on Tuesday, March 6, 2012, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 28, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year... 
Printer Friendly Version
02/06/12ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 9:30 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. ... 
Printer Friendly Version
01/30/12ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Jan. 30, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the election of William (Bill) M. Wells to its board of directors. “We are very pleased to have Bill join ACADIA’s board,” said Uli Hacksell, Ph.D., ACADIA’s Chief Execut... 
Printer Friendly Version